CBP-201, an anti-IL-4Ra antibody, is under evaluation in a Phase 2b clinical trial in atopic dermatitis (AD) patients with moderate-to-severe AD. A Phase 1b study in this population showed CBP-201 was well-tolerated, led to suppression of a serum biomarker of inflammation and rapid improvements in signs and symptoms of AD disease activity. Clinical trials are ongoing for CBP-201 in patients with moderate-to-severe atopic dermatitis (AD), moderate-to-severe persistent asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP).
CBP-307, a small molecule modulator of S1P1, is currently being evaluated in a global Phase 2 clinical study in patients with ulcerative colitis, and we intend to initiate a global clinical trial in Crohn’s Disease (CD). CBP-307 is not a pro-drug and does not require conversion to an active form in the human body following administration.
We are developing CBP-174, a peripherally acting, small molecule H3R antagonist, for oral administration to treat chronic pruritus associated with skin inflammation. CBP-174 is currently being evaluated in a Phase 1 dose-escalation study in healthy subjects. Our preclinical models have indicated that CBP-174 led to reductions in scratching in mice within the first 30 minutes of dosing, which could potentially translate to rapid reduction in pruritus in the clinic.
Connect Biopharma is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research.
With operations and expertise in China, the United States and Australia and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent drug candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets.
- Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating CBP-201 in Adult Patients with Chronic Rhinosinusitis with Nasal Polyps
- Connect Biopharma Announces First Patient Dosed in China Pivotal Trial Evaluating CBP-201 in Adults with Moderate-to-Severe Atopic Dermatitis
- Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results